Can Acalabrutinib be taken after surgery?

Acalabrutinib (Acalabrutinib), as a BTK inhibitor, is mainly used to treat B cell-related diseases, such as chronic lymphocytic leukemia (CLL). The decision as to whether a patient can continue acotinib after surgery should be based on the patient's specific condition and type of surgery.

1. Consider the type of surgery: In some cases, patients may need surgery, such as surgery to remove cancer. Doctors usually evaluate the nature and extent of the surgery and the patient's postoperative recovery to decide whether acotinib can be continued.

2. Consider the schedule before and after surgery: Regarding the schedule before and after surgery, doctors may recommend that patients stop taking medications for a period of time before surgery to reduce the risk of surgery-related bleeding. After surgery, doctors may decide whether to resume acotinib based on the patient's postoperative recovery and special post-operative needs.

3. Bleeding risk: Because acotinib may be related to platelet function and increase the risk of bleeding, doctors may recommend stopping the drug before surgery to reduce the risk of bleeding during and after surgery. This decision usually requires close consultation between physician and patient.

4. Comprehensive evaluation before and after surgery: When considering whether to continue using acotinib after surgery, doctors usually conduct a comprehensive evaluation, including the patient's overall health, the complexity of the surgery, and the therapeutic effect of the drug. This helps ensure the most appropriate treatment plan is developed before and after surgery.

5. Postoperative monitoring: If the patient recovers well after surgery, the doctor may consider resuming acotinib after surgery. However, postoperative monitoring remains critical to ensure the patient's overall condition and drug tolerance.

In general, deciding whether to continue using acotinib after surgery is an individualized process that requires comprehensive consideration by the doctor based on the patient's specific situation. Patients should maintain close communication with their doctors to jointly develop a treatment plan that suits them, and receive regular medical monitoring to ensure the best treatment effect.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.